Survival Boost
Judy Siegel-Itzkovich, THE JERUSALEM POST
The monoclonal antibody drug Rutiximab (commercially known as Mabtera) has been shown to reduce mortality by an amazing 40 percent in follicular lymphoma patients; 400 new cases are diagnosed each year.
This was proven in research at the Rabin Medical Center-Beilinson Campus that was published recently in the prestigious Journal of the [US] National Cancer Institute.
The meta-analysis of a number of previous controlled studies included Mabtera treatment on 985 patients who were followed up for three years. Dr. Liat Vital of the Davidoff Cancer Center on the Petah Tikva campus said most patients with this kind of blood cancer have relapses.
If this immunological treatment is given following chemotherapy, she added, survival rates soar. Prof. Ofer Sperling, head of the hematology department there, said such patients should receive Mabtera for two years after a relapse of the lymphoma and that it should become standard treatment for all cases. The Rabin Medical Center research, he continued, will help lengthen the survival of many patients around the world.
Related Articles
Study at Rabin Medical Center On Induced Labor Shows No Harm to Mothers & Babies
Tel Aviv University study has determined that natural, spontaneous deliveries and induced deliveries following the rupture of the amniotic sac in the mother share similar neonatal outcomes, contradicting common wisdom.
Heart Surgeries Televised Globally
The prestigious Division of Cardiology at Rabin Medical Center, headed by Prof. Alexander Battler, is the leading facility for heart patients in Israel.
Staying Strong During Cancer
As if being stricken with cancer isn't enough, there are many cancer patients whose immune systems become so weakened by chemotherapy treatments that they become prone to life threatening infections.